Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis
1 other identifier
observational
527
0 countries
N/A
Brief Summary
The aim of the retrospective study was to further characterize the prevalence of comorbid conditions as well as the use of concomitant medications in newly diagnosed CML patients in a real-world setting. Hematologists from ten Polish hematological tertiary care centers were asked to analyze medical records for all consecutive CML patients diagnosed with chronic phase CML between January 1st 2005 and December 31st 2014.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2016
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2016
CompletedFirst Submitted
Initial submission to the registry
September 11, 2023
CompletedFirst Posted
Study publicly available on registry
September 18, 2023
CompletedSeptember 18, 2023
September 1, 2023
5 months
September 11, 2023
September 16, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
the prevalence of comorbid conditions in newly diagnosed CML patients
data collected through an on-line questionnaire, descriptive data
February - July 2016
the number of concomitant medications in newly diagnosed CML patients
data collected through an on-line questionnaire, descriptive data
February - July 2016
Study Arms (1)
newly diagnosed CML patients
Interventions
analysis of history of comorbidities at the time of CML diagnosis
Eligibility Criteria
Adult patients with diagnosis of chronic phase CML diagnosed between January 1st and December 31st 2014, treated with TKI (imatinib, dasatinib, nilotynib)
You may qualify if:
- \) age ≥ 18 years; 2) diagnosis of chronic phase CML between January 1st 2005 and December 31st 2014.
You may not qualify if:
- primary diagnosis of CML in accelerated or blastic phase
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Gora-Tybor J, Sacha T, Waclaw J, Niesiobedzka-Krezel J, Grzybowska-Izydorczyk O, Medras E, Deren-Wagemann I, Patkowska E, Seferynska I, Lewandowski K, Wache A, Blajer-Olszewska B, Watek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K. Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):e283-e285. doi: 10.1016/j.clml.2018.05.001. Epub 2018 May 9. No abstract available.
PMID: 29778693RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Project Manager of Polish Adult Leukemia Group
Study Record Dates
First Submitted
September 11, 2023
First Posted
September 18, 2023
Study Start
February 1, 2016
Primary Completion
July 1, 2016
Study Completion
August 1, 2016
Last Updated
September 18, 2023
Record last verified: 2023-09